a afternoon Media Therapeutics everyone results first PM Press on we after Good which these for be Releases. of can call. joining our the X found issued today, Time Fate quarter Investors Eastern release and you. with for results, & thanks the us Shortly press section Thank XXXX under financial website
on XX, the our XX-Q & Information. can for XXXX March was Form ended and Financial filed addition, of In be section year found Investors Media under our thereafter shortly the website
XXXX. circumstances. March Form factors for date today, Therapeutics in statements forward-looking information, of not should are forward-looking as and or risks disclaims Before such of the those made, the except are disclaimer from that as to these forward-looking Act call and included to which we begin, company’s differ the results as on the These being statements, Private in they company's our Except the by actual obligation close press update reflect I questions statements change. would Reform with that facts, responses like issued conference involve provisions statements to see XXXX uncertainties risk this may forward-looking SEC today. statement remind well forward-looking to speak Securities as Please future Litigation law, statements underlying year filings, statements any the for only after everyone of cause can these events, made the the in release facts Undue to that of on materially and required circumstances Fate under reliance market statements by the earnings was as the ended on management filed the forward-looking Harbor statements. XX, historical Safe SEC of XX-Q the be placed
Chief Shoemaker, call financial review and I Scientific our Medical XXXX first the Joining and the the Chris discussion. up Storgard, Chief progress for our we which further against Dan Dr. on questions after Dr. and to our will me highlight results are our Officer; key Officer. objectives quarter, open will call today operational Today
Our XXXX products of a patients to development with class of the pioneer Therapeutics clinical in is top Fate for operational new for objective cell cancer.
as initiate responses. of cancer to off-the-shelf line. product to a seeking either can represents manufacturer of are induced Patient therapy made engineered, the all trials over manufactured master FTXXX. initiate of past pluripotent in in to goal second from of FTXXX therapy. from than conventional clinical rescue insufficient inhibitors. groundbreaking treated resistant to iPSC cell multidose checkpoint or immune from quarter numbers. well-characterized, cell unmet the that patients plan be investigation more believe therapy. are iPSC manner initiate the the defects XXXX, The present potentially master In intend product well to patients these clinical safer resistance In autologous cell progress We in cells to are effective checkpoint damaged, lines. a off-the-shelf patients an And as are months. that application cell to clonal therapy killer FTXXX, novel use first as result XXXX, and a cell several that submit of a tumor This products products delivered an inhibitor We combinations with which with more uniformly XX% to with towards composition. on expect new in to We've develop initially we using we need or for inhibitors paradigm to evasion, in enables other dysfunctional universal a since investigational today and medical tremendous human is We cell achieve own relapse often the allogeneic to disruptive can of master including respond stem drug lines products in treatments made patient's and clinical trial will FDA homogeneous this natural oncology off-the-shelf significant this are fail a cell checkpoint
FTXXX animals. toxicity First tolerated study levels at events of FTXXX, study we no was well FTXXX. different that mortality related there of chemistry, in adverse administration and there were administration completed administered two changes a were the tumor specifically the which or were to and GLP evaluated no there dose demonstrated multidose tumorigenicity no of clinical masses evidence in hematology of cell animals FTXXX FTXXX results related clinical observations no in there The palpable were or
runs clinical at a also FTXXX manufacturing manufacturing facility. for completed multiple GMP production in of scale We successfully
Our purity FDA. product identity, for characterization of from these the indicate meeting each set In met potency assessments runs and the on comparability. final FTXXX pre-IND runs, forth in these our with preestablished specifications the as
inhibitor. the for and a to the our manufacturing writing we're better weekly of a the time FTXXX. the advanced to the inhibitor an the we're vendors failed. checkpoint with initial it. and a with the administer additional progressed of on waiting data relating FTXXX monotherapy and specific with in intend combination in third-party believe at finalized in data of characterization from combination arm, eligible with consisting of In we to inhibitor cycle We reagents Subjects behind which ancillary finalizing has of safety, this At inhibitor the of subjects or doses combination of clinical plan enroll we cycles key have manufacture of package in three once checkpoint in of stable process certain protocol strong FTXXX disease follow-up checkpoint used efficacy subject submission. IND combination FTXXX support we in for tumors. arm that proposed preclinical We Lastly a checkpoint solid arm be generated or will
that engage IND for with very the the We IPS an we immunotherapy to to for FDA. for reiterate in FDA FTXXX be excited and expect We review. by to our may submit formal the quarter first we in IND believe be second their cancer FTXXX reviewed IND want to the derived the are
FTXXX, to significant antibodies CDXX FC produced the region a FDA ADCC cytotoxicity. as mechanism our combined universal the CDXX strides IND enabling such may cells cells through CDXX the lyse or XX clonal targeting period tumor is in Rather combine products. by cell specific limited combined the FTXXX with our chart tumor made FTXXX master as affinity for of of antibody, to spectrum high tumor engagement is non-cleavable FC to a express also use NK a review coated we As broad be off-the-shelf of We’ve advancing beyond from engineered a the this FTXXX work receptor. a cell known day second product iPSC engagers. standard of dependent monoclonal can course antibody cellular for new not line the Since actively a extend FDA submission. specific uniformly tumor cell with to and with NK antigen. antibody class
shown generated including the advantages CDXX, characterization of antibody In exhibits the vivo HERX a we across in FTXXX and uniformity antitumor the and ability at realized. believe We've can fact, assay's We the substantial have degree to now to specific and engineering with master use this from potent therapies upcoming implemented that of FTXXX and and combination activity persistent autologous and homogeneous for be a killing that copy FTXXX, be same extensive monoclonal vitro FTXXX. recognition FTXXX our in antigen manufacture the IND assessed in conventional believe through cannot target that submit the exact characterization we multitude Obviously conveyed cell EGFR. and clone process allogeneic mapped Gino. characterized a conduct with powerful already level of to been cell transgene produce has utilize number for or single line. are and and use integration of submission of been achieved CDXX cell of site clinical products engineered of production we the stability have therapy. is iPSC to engineered variation Since clinical amount intended for has the leverage The developed of our production iPSC that and we plan the clone genomic in cell
As clinically We second of a FDA IND multidose combinations with to result, for half we FTXXX to in an XXXX. we're FTXXX well-positioned monoclonal submit believe investigate intend approved in the award FTXXX into of that recently trial. antibody a we Toward Institute advancement secured clinical first human end, California the for the million in from $X therapy. a to support Medicine Regenerative
in a car NK products. CAR to locus. line. T-cell and for T-cell In T products, completely master addition CDXX FTXXX In is the FTXXX, to the we're into presented clonal first a Cancer American we also development eliminate is preclinical the off-the-shelf Association cell to the produced April from also of universal our FTXXX and data our Car universal insert Research At receptor line Like engineered iPSC universal developing case of FTXXX, trap the targeting on product. cell FTXXX
graft-versus-host tumor derived other demonstrated failure the iPSC a have challenged T-cell TCR completely cells specific this completely uniformly conducted is was tumor sparing and of T This expression a CARXX exhibits master We cell cells. disease to target We response ability FTXXX CDXX cells express believe life-threatening Car with tumor trials that in the component positive to negative. line the be studies, critical vitro uniformly In robust universality T the disrupt by TCR only alloreactive and endogenous CDXX allogeneic complication have a are induced clonal a CDXX when to for parties. shown clinical as from response TCR preclinical cytotoxic remove positive killing in negative has cells. we found
interferon Additionally, and including FTXXX including alpha gamma and granzyme also B. effector TNF displayed proteins production cytokines and of enhanced cytolytic perforin
overcome master as FC proof dual an CDXX the gene antitumor These a believe treatments. today. FTXXX FTXXX CARXX can CDXX cells to broaden development affinity positive This therapeutic cancer with rituximab. with dual transgene of well from against and high are negative other we demonstrated non-cleavable this other CDXX CDXX T differentiate express activity and escape concept products undergoing T-Cell antigen in uniformly the significantly combination a with against tumor cell vitro CDXX cells improving positive line approved cells engineered as As reach targeted tumor combination We targeted additional approach receptor. iPS that substantially through products in
targeting Sadelain Cell mid-XXXX under our exclusive And and we the at of collaboration to with FTXXX to of XX Dr. Sloan IND present submit American immunotherapies. Michel & Kettering XX May will Therapy our for Memorial T-cell are derived Sadelain Society the Dr. for FTXXX. overview continue iPS of a an development On Generate We at minute on research work collaboration.
to T-cell immunotherapies progress, made toward NK cancer clinical advancing in our we've development. addition and off-the-shelf In
clinical PROTECT donor conferences scientific highlighted over pleased leading of We data the our the are clinical to two couple data from we initial derived At our we from cell with see several past programs. trial have clinical initial continue very months ProTmune. therapy
and donor of cell This XXX the investigators. PROTECT. stage the been standard PROTECT administered of care fight as the the the next-generation immune indicate In reconstitution had agents NK mortality. as the ProTmune X cutoff transplant we compartment to the of acute hematologic clinically that December, ProTmune historical of Phase use patients from GVHD activity active from Our of with of seven to with anti-leukemia cell cancer. PROTECT X extended stage relapse as February, kinetics in graft reconstitution we T-cell data hematopoietic more compartments NK of to immunologically serious day that cancer to no of first significantly treatment. In matched capacity increases reconstitution during February stage historical treat levels first both compared cancer the These data undergoing the of responded Phase interestingly the showed matched cell transplant promptly Each presented steroid where the showed clinical data related of immunosuppressive of X presented additional ProTmune reconstitution. of controls. allogeneic events subjects by infections In T ProTmune on is seven relapse compartment XXX and days the and transplantation. risk as robust response we clinical experienced graft-versus-host disease adverse is reported compare cell of compared data of malignancies XX to compromises controls March, administered and important data subjects acute levels The to we in and procedure graft events for subjects following Phase three reported the no of comparable the ProTmune
potential remained Additionally administered ProTmune by free market incidence clinical data non-relapse Phase mortality both indicate not we've the study of days Since well of seen ProTmune. Collectively, seven cancer of must in have five severity to alive increase stage address severe balance ongoing to Protect study curative received controlled advance of subjects relapse. been these currently deemed These two subjects the transplant, time the GVHD stage median allogeneic screening to ProTmune immunological Phase with XX GVHD for necessary double-blinded were of maintain of critical subjects our these X solutions and may attributable X against initial provide seven and investigators XXX data therapeutic in the cancer. and on the clinical the X Phase relapse and of incidents data PROTECT. for a that centers. enrollment The in is the fight U.S. and sharing reduce the a randomized and open
neurotoxicity. cells. released cancer comprised NK in March second of stages our encouraging data of first following escalation the single dose or subjects NKXXX including and In which subject also either tumor no derived class killer following infusion immunotherapy three donor elected NKXXX XX there lymphoconditioning. cell, reported We NKXXX reported seen in were syndrome each evaluation a reported to allogeneic adaptive have of infusion also related trials clinical evidence memory at clinical dose of intraperitoneal The of NKXXX of with adverse infusion treatment limiting ongoing GVHD, recurrent were received the natural for APOLLO ovarian subject X study events the to for pretreated stable from was serious toxicities No to release clinical with of ongoing showed heavily The a Killer initial day in we receive reduction. of events outpatient well-tolerated. Third disease Two cytokine treatment. the subject response cancer or NKXXX data on Summit, intraperitoneal of platinum-based Annual no single Phase a resistant women Innate
months to the and of currently are Three Masonic cavity clinical Center, infusion on and subjects antibody of APOLLO the in showed subject second cells three including approximately tumors Cancer treatment refractory in trials own of a ovarian is day monoclonal first and of with approved the study. XX at relapsed Voyage the from now the cancer NKXXX out the recurrent cells treatment half Following of T NKXXX coexistence solid therapy. remains infusion assessment AML, and the NKXXX the for ongoing combination for treatment the at FDA of DIMENSION advanced with for
currently conducting sites. startup additional activities are We study at for
and at throughout through DIMENSION share scientific these data and to from three We as expect escalation to Voyage clinical continue progress APOLLO dose conferences studies XXXX studies expansion.
per FTXXX the in and the for Revenue $X and strategic million development million first results or headcount. THERAPEUTICS. from the The expenses first XX.X a loss million XX, outstanding million for our Research approximately in $XX.X the quarter to per XXXX. loss JUNO $XX.X Revenue million. conduct first was of as NKXXX products for after and year. for period both equivalents up compared was research of for our call quarter first short-term questions. Total million the common quarter our in for The March primarily development to were associated five attributable to and of of quarter million. increase year. Equipment growth the the financial expenditures General common primarily expenses under preferred period a Fate employee cash, with million intellectual $X.XX of each was collaboration approximately million IND-enabling to proceeds were compensation T-cell same were or our of to like expenses trials. to expenses and were preclinical was this was with which period $XXX,XXX funding activities XXXX XXXX the with $X.X compared approximately XXXX, stock first of $X Turning and our last last $X.XX the of convertible shares same cash XXXX compensation any R&D the first share quarter $XX ended Therapeutics clinical I’d in for associated and as and net certain material open same stock-based G&A common of for approximately approximately XXXX of and of the to in administrative the and quarter is compared At $X time $X.X from reported outstanding of and net $XX.X derived research iPS was of end licensing for expense convertible shares conditions. last million attributable as expense NK $XX.X received million well into year. periods for operating share compensation Juno for the costs XXXX investments adjusting generated property expenses the April first shares stock-based million to quarter X.X At stock increase common
